Thomas Daniel-Robin, BD Director, will be attending ISPOR Europe 2022 held in Vienna from November 6-9 to present a poster on recently published data on Wilson disease.

This leading European conference for Health Economics and Outcomes Research is the ideal place to present the results of Vivet’s study of Wilson disease patients data in the French national SNDS database / Health Data Hub (HDH): https://www.sciencedirect.com/science/article/pii/S2210740122001267?via%3Dihub

Close to 2,000 patients have been identified in this database and more than 1,500 patients analyzed for up to 11 years. A great basis for better understanding and disease awareness.
? 12% received disability compensation during the study period (2009-2019)
? 27.2% took over six months’ sick leave and 75% were hospitalized during the year post diagnosis
? And 34-42% were hospitalized each year during the 10-year follow-up period

These results further highlight the high unmet medical needs in Wilson disease.

? 56% of them did not receive standard of care medication
? 67% showed at least one clinical manifestation post diagnosis and still 56% have clinical manifestations 11 years post diagnosis
? Unexpected significant higher premature mortality: 13.8% of WD patients died over the study period. Average age at death of 58

Vivet is doing further analysis of these data and exploring other healthcare databases in the USA and Japan.